Seeking Alpha

Shares of Orexigen (OREX -4.8%) slip deeper into the red today after it reported a Q4 that beat...

Shares of Orexigen (OREX -4.8%) slip deeper into the red today after it reported a Q4 that beat on a per share basis, but came up short on revenue. The company reported a loss of $0.41 per share, versus the consensus of a $0.44 per share loss. Revenues were $857K, below analyst estimates of $890K. Total operating expenses were significantly higher for the quarter, coming in at $33.3M compared to $5.2M in Q411, reflecting higher R&D expenses associated with the conduct of its Contrave cardiovascular outcomes trial. Read more on earnings here: Earnings Call Transcript.

Check out Seeking Alpha’s new Earnings Center »

Comments (1)
  • Yabadabadoo
    , contributor
    Comments (447) | Send Message
     
    Still a good speculative stock; wait for it to come down more. When the market comes down, OREX will move down as well. $5.50 and think of buying. Just remember, OREX is a speculative stock.
    14 Mar 2013, 05:47 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs